Genomics and Epigenetics of Malignant Mesothelioma.
High Throughput
7:
2018
E20
|
26
|
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
Nat Commun
10:
2019
1333
|
90
|
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
EBioMedicine
48:
2019
191-202
|
42
|
Integrated genomics point to immune vulnerabilities in pleural mesothelioma.
Sci Rep
11:
2021
19138
|
12
|
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
Br J Cancer
127:
2022
1691-1700
|
2
|
Artificial Intelligence Techniques to Predict the Airway Disorders Illness: A Systematic Review.
Arch Comput Methods Eng
30:
2023
831-864
|
10
|
Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment.
Mol Oncol
16:
2022
3949-3974
|
2
|
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
Mol Oncol
18:
2024
866-894
|
4
|
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma.
JTO Clin Res Rep
3:
2022
100430
|
3
|
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
Clin Cancer Res
29:
2023
548-559
|
13
|
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.
Cell Rep Med
4:
2023
100915
|
6
|
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
Clin Transl Med
13:
2023
e1190
|
2
|
The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition.
Int J Mol Sci
24:
2023
2874
|
0
|
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity.
Nat Genet
55:
2023
607-618
|
17
|
A Novel Two-Gene Expression-Based Prognostic Score in Malignant Pleural Mesothelioma.
Diagnostics (Basel)
13:
2023
1556
|
0
|
Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma.
NPJ Precis Oncol
8:
2024
47
|
1
|
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.
Front Toxicol
6:
2024
1373003
|
1
|
BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.
Cancer Gene Ther
None:
2024
None
|
0
|
Mesothelioma survival prediction based on a six-gene transcriptomic signature.
iScience
27:
2024
111011
|
0
|